ArticleRheumatology (Oxford, England)2020

Comment on: Long-term efficacy and safety of tocilizumab in refractory Takayasu arteritis: final results of the randomized controlled phase 3 TAKT study: reply.

Yoshikazu Nakaoka et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.